Effects of Glucosamine on Joint Fluid in Osteoarthritis Patients
Investigation of Oral Glucosamine Effects on Synovial Fluid Viscosity and Viscoelasticity in Osteoarthritis Patients
1 other identifier
interventional
20
1 country
2
Brief Summary
Osteoarthritis (OA) is the most common joint disease associated with aging. Although many patients take glucosamine supplements as a non-traditional treatment for osteoarthritis, the effectiveness of these supplements is questionable. This study will evaluate glucosamine therapy by directly analyzing two functions of joint fluid that are impaired by osteoarthritis - namely, the abilities to lubricate the joint and absorb shocks during activity. Joint fluid samples will be collected from subjects with knee osteoarthritis and analyzed on a device that simulates typical joint movements. After 3 months of glucosamine supplementation, samples will be collected again to detect potential improvements in joint fluid function.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable knee-osteoarthritis
Started Jun 2015
Typical duration for not_applicable knee-osteoarthritis
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 22, 2010
CompletedFirst Posted
Study publicly available on registry
February 24, 2010
CompletedStudy Start
First participant enrolled
June 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2017
CompletedJune 29, 2016
June 1, 2016
2 years
February 22, 2010
June 28, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Changes in synovial fluid viscosity and viscoelasticity compared to baseline
3 months
Secondary Outcomes (1)
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score
3 months
Study Arms (2)
1
EXPERIMENTALGlucosamine sulphate tablets
2
PLACEBO COMPARATORPlacebo tablets
Interventions
750mg glucosamine sulphate (oral tablets), twice per day for 3 months
Eligibility Criteria
You may qualify if:
- are between 30 and 85 years of age
- are clinically diagnosed with moderate to severe knee OA
- are recommended for synovial fluid aspiration
You may not qualify if:
- are clinically diagnosed with inflammatory arthritis
- had previous joint surgery in the study knee
- had injection in the study knee within the past 12 months
- have taken glucosamine and/or chondroitin supplements within the past 3 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
OASIS Vancouver Clinic, Gordon & Leslie Diamond Health Care Centre
Vancouver, British Columbia, V5Z 1M9, Canada
University of British Columbia Health Clinic
Vancouver, British Columbia, V6T 1Z3, Canada
Related Publications (7)
Fam H, Bryant JT, Kontopoulou M. Rheological properties of synovial fluids. Biorheology. 2007;44(2):59-74.
PMID: 17538199BACKGROUNDAnadere I, Chmiel H, Laschner W. Viscoelasticity of "normal" and pathological synovial fluid. Biorheology. 1979;16(3):179-84. doi: 10.3233/bir-1979-16306. No abstract available.
PMID: 508928BACKGROUNDSchurz J, Ribitsch V. Rheology of synovial fluid. Biorheology. 1987;24(4):385-99. doi: 10.3233/bir-1987-24404.
PMID: 3663897BACKGROUNDVangsness CT Jr, Spiker W, Erickson J. A review of evidence-based medicine for glucosamine and chondroitin sulfate use in knee osteoarthritis. Arthroscopy. 2009 Jan;25(1):86-94. doi: 10.1016/j.arthro.2008.07.020. Epub 2008 Sep 30.
PMID: 19111223BACKGROUNDBlack C, Clar C, Henderson R, MacEachern C, McNamee P, Quayyum Z, Royle P, Thomas S. The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation. Health Technol Assess. 2009 Nov;13(52):1-148. doi: 10.3310/hta13520.
PMID: 19903416BACKGROUNDClegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO 3rd, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR Jr, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006 Feb 23;354(8):795-808. doi: 10.1056/NEJMoa052771.
PMID: 16495392BACKGROUNDMatsuno H, Nakamura H, Katayama K, Hayashi S, Kano S, Yudoh K, Kiso Y. Effects of an oral administration of glucosamine-chondroitin-quercetin glucoside on the synovial fluid properties in patients with osteoarthritis and rheumatoid arthritis. Biosci Biotechnol Biochem. 2009 Feb;73(2):288-92. doi: 10.1271/bbb.80418. Epub 2009 Feb 7.
PMID: 19202302BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ezra Kwok, Dr
University of British Columbia
- STUDY DIRECTOR
Dana Grecov, Dr.
University of British Columbia
- STUDY DIRECTOR
Christie Newton, Dr.
University of British Columbia
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 22, 2010
First Posted
February 24, 2010
Study Start
June 1, 2015
Primary Completion
June 1, 2017
Study Completion
June 1, 2017
Last Updated
June 29, 2016
Record last verified: 2016-06